首页 › 基金 › Prosight Management, LP › LKFT
Prosight Management, LP 对 LKFT 的持仓历史
LAKEFRONT BIOTHERAPEUTICS NV
Prosight Management, LP 在 Q3 2026 的 13F 申报中披露持有 LKFT(LAKEFRONT BIOTHERAPEUTICS NV)1,998,400 股,市值约 US$59.3M,约占其申报组合的 11.49%,在其申报持仓中市值排名第 1 位。 Prosight Management, LP 最近 13 个申报季度中有 13 个季度披露了 LKFT 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Prosight Management, LP 对 LKFT 的持仓演变
Prosight Management, LP 于 Q3 2023 首次披露 LKFT 持仓:730,207 股(约 US$25.2M)。 该持仓在 Q2 2026 达到峰值 2,043,344 股,市值约 US$61.3M。 在 13 次申报中,Prosight Management, LP 7 次增持、4 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 1,998,400 股、市值约 US$59.3M,环比减持 -44,944 股。。 持仓曾出现大幅变动:Q2 2024 增持约 45% (随后一个季度股价上涨 16%)、Q3 2025 减持约 35% (随后一个季度股价下跌 6%)、Q1 2026 增持约 44% (随后一个季度股价基本持平)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 730.21K | $25.23M | 新进 |
| Q4 2023 | 827.29K | $33.63M | 增持 |
| Q1 2024 | 931.51K | $29.99M | 增持 |
| Q2 2024 | 1.35M | $33.45M | 增持 |
| Q3 2024 | 1.03M | $29.62M | 减持 |
| Q4 2024 | 1.02M | $28.19M | 持有 |
| Q1 2025 | 1.31M | $33.03M | 增持 |
| Q2 2025 | 1.77M | $49.64M | 增持 |
| Q3 2025 | 1.15M | $39.84M | 减持 |
| Q4 2025 | 1.07M | $35.12M | 减持 |
| Q1 2026 | 1.55M | $46.50M | 增持 |
| Q2 2026 | 2.04M | $61.26M | 增持 |
| Q3 2026 | 2.00M | $59.25M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 LKFT 与 13F 数据
LKFT(LAKEFRONT BIOTHERAPEUTICS NV)的行业分类暂缺。我们追踪的基金中还有 20 只申报持有 LKFT,申报仓位最大的包括:GILEAD SCIENCES, INC. (US$501.3M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 LKFT 的基金
- GILEAD SCIENCES, INC. 16.71M 股 · $501.28M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M 股 · $113.50M · Q2 2026
- Madison Avenue Partners, LP 3.45M 股 · $103.37M · Q2 2026
- EcoR1 Capital, LLC 1.67M 股 · $49.98M · Q2 2026
- DME Capital Management, LP 482.75K 股 · $14.47M · Q2 2026
- DAFNA Capital Management LLC 130.18K 股 · $3.90M · Q2 2026
更多关于 Prosight Management, LP
常见问题
How long has Prosight Management, LP held LKFT?
Prosight Management, LP has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Prosight Management, LP's current position in LKFT?
As of Q3 2026, Prosight Management, LP holds 2.00M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $59.25M, representing 11.49% of its reported portfolio and ranking #1.
Has Prosight Management, LP been buying or selling LKFT?
In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in LKFT. The position peaked in Q2 2026 at 2.04M shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.